Avid Bioservices Inc (CDMO)

[biopharm]

Paul - evidence is strongly mounting support your comments from complimentary sources. In a type of concurrence with importance of PS blockade - except across its receptors on the T-Cell side of things.

Many are aware that TIM-3 and LAG-3 are two of several checkpoints that bind to PS. Not sure how many are aware that the rate of clinical trials evaluating these two checkpoint inhibitors is rising, and that multiple smaller scale trials are showing great results using that combo. That is driving the greater investment and expansion of trials.

Why is that a good thing? All these combo trials are conducted by large pharma companies who are seeing supporting signals to increase investment.
...
....

MH, there is solid research detailing BPs working PS Targeting now into their patent filings .....so validation is there and wonder what is your take on these patent filings by others....with Peregrine patents embedded...possibly cross licenses already have taken place...?

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=133777959


Much more to come it seems....
https://www.google.com/amp/s/www.bna.com/dana-farber-says-n57982059025/%3famp=true